Joelf Posted December 2, 2020 Share Posted December 2, 2020 Evaluation of Malignancy Risk in Scleroderma (SSc) by Antibody Profile. A close temporal relationship between onset of SSc and malignancy has been reported in patients with anti-RNA polymerase III antibody. PubMed, Br J Dermatol, 09/13/2020. (Also see Cancer) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. Quote Link to post Share on other sites
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.